Chardan Capital Reiterates Buy Rating for Zura Bio (NASDAQ:ZURA)

Zura Bio (NASDAQ:ZURA)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $10.00 target price on the stock.

Separately, Oppenheimer cut their price target on Zura Bio from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Friday, May 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Zura Bio presently has an average rating of “Buy” and an average price target of $14.17.

Zura Bio Stock Performance

NASDAQ ZURA opened at $1.66 on Friday. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $5.07. The stock has a market cap of $113.51 million, a P/E ratio of -2.37 and a beta of -0.06. The stock has a 50 day simple moving average of $1.37 and a two-hundred day simple moving average of $1.32.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. Sell-side analysts predict that Zura Bio will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Zura Bio

Large investors have recently made changes to their positions in the business. Millennium Management LLC lifted its position in shares of Zura Bio by 1,499.0% in the fourth quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after acquiring an additional 657,420 shares in the last quarter. Barclays PLC lifted its position in shares of Zura Bio by 22.6% in the fourth quarter. Barclays PLC now owns 78,523 shares of the company’s stock valued at $197,000 after acquiring an additional 14,462 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Zura Bio by 12,060.8% in the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock valued at $6,583,000 after acquiring an additional 2,611,532 shares in the last quarter. ProShare Advisors LLC purchased a new position in shares of Zura Bio in the fourth quarter valued at about $35,000. Finally, Renaissance Technologies LLC lifted its position in shares of Zura Bio by 102.1% in the fourth quarter. Renaissance Technologies LLC now owns 129,114 shares of the company’s stock valued at $323,000 after acquiring an additional 65,214 shares in the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.